AMG' has unveiled its high-performance concept car 'Concept AMG GT XX' with excellent technology, ultra-fast charging and ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US ...

Mercedes-Benz is recalling more than 90,000 cars. Here's what to do if you're impacted. Mercedes-Benz is recalling more than 90,000 cars. ... Blueprint WITNESS (True Crime) ...

Sanofi is paying $129 per share in cash for Blueprint, amounting to a $9.1 billion equity value and a 27% premium on the biotech’s closing price on Friday.

Sanofi agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker’s biggest move yet to replenish its drug pipeline since it sold a controlling stake in its consumer ...

At the lectern, Jacobs had clear calls for action for would-be do-gooders in the crowd. Get on Blueprint’s listserv. Scan the QR codes scattered across the room for more information. “Get informed, ...

The Blueprint for Maryland’s Future — a plan to improve public schooling that calls for starting childhood education at an earlier age, increasing pay for teachers and bolstering career and ...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European ...

Blueprint Medicines is revising a pact with VantAI again, this time adding a focus for historically “undruggable” targets and prioritizing new target-effector pairs that could be used to ...

Mercedes-Benz G580 battery-electric SUVs maintain the iconic design and off-road capability with an all-new powertrain. ... "There was no blueprint for the G-Turn—we started from scratch.

The two companies said on Monday that Sanofi would initially pay $129.00 per share in cash, or around $9.1 billion. Blueprint shares jumped 27% to $128.74 in premarket trade.